<code id='FCC822F9DC'></code><style id='FCC822F9DC'></style>
    • <acronym id='FCC822F9DC'></acronym>
      <center id='FCC822F9DC'><center id='FCC822F9DC'><tfoot id='FCC822F9DC'></tfoot></center><abbr id='FCC822F9DC'><dir id='FCC822F9DC'><tfoot id='FCC822F9DC'></tfoot><noframes id='FCC822F9DC'>

    • <optgroup id='FCC822F9DC'><strike id='FCC822F9DC'><sup id='FCC822F9DC'></sup></strike><code id='FCC822F9DC'></code></optgroup>
        1. <b id='FCC822F9DC'><label id='FCC822F9DC'><select id='FCC822F9DC'><dt id='FCC822F9DC'><span id='FCC822F9DC'></span></dt></select></label></b><u id='FCC822F9DC'></u>
          <i id='FCC822F9DC'><strike id='FCC822F9DC'><tt id='FCC822F9DC'><pre id='FCC822F9DC'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:entertainment    - browse:155

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot